RESUMEN
Amino groups of amino acids, nucleic acids and lipids can react non-enzymatically with reducing sugars to form unstable Schiff bases that can then undergo the Amadori rearrangement to form irreversible advanced glycation end products (AGEs). Ketoacidosis is a life-threatening complication in patients with untreated diabetes mellitus and it is characterized by increased circulating ketone body concentrations. Recently, the in vitro glycation of hemoglobin by beta-hydroxybutyrate and acetone was described by our laboratory. This study was designed to evaluate the in vitro effect of acetoacetate on brain aminophospholipids at similar concentrations to that observed in ketoacidosis (16.13 mM total ketone bodies). The effect of acetoacetate was compared to that of glucose and the other ketone bodies; beta-hydroxybutyrate and acetone. The antiglycating activity of urea and glycylglycine was also investigated. The incubation of aminophospholipids with acetoacetate results in the formation of a new compound with an absorption peak at 280 nm. When this reaction product was analyzed by thin layer chromatography using an elusion system of methanol:chloroform:acetic acid:water (8:1:1:0.4), the R(f) value obtained (0.24-0.26) was similar to that of the compound formed by aminophospholipids with glucose. In contrast, this reaction product was not detected in those samples containing beta-hydroxybutyrate and acetone. The formation of this new compound was inhibited by urea more effectively than glycylglycine. In conclusion, this study provides the evidence that brain aminophospholipids react with acetoacetate forming AGEs and that this glycating effect of acetoacetate was remarkably decreased by urea, suggesting a protective physiological role for urea in the body as it was previously stated. Finally, this information adds knowledge about the contribution of ketoacidosis in the pathophysiology of diabetic complications, especially in type 1 diabetic patients.
Asunto(s)
Acetoacetatos/antagonistas & inhibidores , Acetoacetatos/farmacología , Química Encefálica/efectos de los fármacos , Fosfolípidos/metabolismo , Urea/farmacología , Animales , Bovinos , Cromatografía en Capa Delgada , Glucosa/farmacología , Productos Finales de Glicación Avanzada/análisis , Productos Finales de Glicación Avanzada/química , Glicilglicina/farmacología , Cuerpos Cetónicos/farmacología , Lípidos/química , Lípidos/aislamiento & purificación , Espectrofotometría UltravioletaRESUMEN
Mitochondrial beta-ketothiolase and 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiencies are inherited neurometabolic disorders affecting isoleucine catabolism. Biochemically, beta-ketothiolase deficiency is characterized by intermittent ketoacidosis and urinary excretion of 2-methyl-acetoacetate (MAA), 2-methyl-3-hydroxybutyrate (MHB) and tiglylglycine (TG), whereas in MHBD deficiency only MHB and tiglylglycine accumulate. Lactic acid accumulation and excretion are also observed in these patients, being more pronounced in MHBD-deficient individuals, particularly during acute episodes of decompensation. Patients affected by MHBD deficiency usually manifest severe mental retardation and convulsions, whereas beta-ketothiolase-deficient patients present encephalopathic crises characterized by metabolic acidosis, vomiting and coma. Considering that the pathophysiological mechanisms responsible for the neurological alterations of these disorders are unknown and that lactic acidosis suggests an impairment of energy production, the objective of the present work was to investigate the in vitro effect of MAA and MHB, at concentrations varying from 0.01 to 1.0 mmol/L, on several parameters of energy metabolism in cerebral cortex from young rats. We observed that MAA markedly inhibited CO2 production from glucose, acetate and citrate at concentrations as low as 0.01 mmol/L. In addition, the activities of the respiratory chain complex II and succinate dehydrogenase were mildly inhibited by MAA. MHB, at 0.01 mmol/L and higher concentrations, strongly inhibited CO2 production from all tested substrates, as well as the respiratory chain complex IV activity. The other activities of the respiratory chain were not affected by these metabolites. The data indicate a marked blockage in the Krebs cycle and a mild inhibition of the respiratory chain caused by MAA and MHB. Furthermore, MHB inhibited total and mitochondrial creatine kinase activities, which was prevented by the use of the nitric-oxide synthase inhibitor L-NAME and glutathione (GSH). These data indicate that the effect of MHB on creatine kinase was probably mediated by oxidation or other modification of essential thiol groups of the enzyme by nitric oxide and other by-products derived from this organic acid. In contrast, MAA did not affect creatine kinase activity. Taken together, these observations indicate that aerobic energy metabolism is inhibited by MAA and to a greater extent by MHB, a fact that may be related to lactic acidaemia occurring in patients affected by MHBD and beta-ketothiolase deficiencies. If the in vitro effects detected in the present study also occur in vivo, it is tempting to speculate that they may contribute, at least in part, to the neurological dysfunction found in these disorders.
Asunto(s)
Acetoacetatos/farmacología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/embriología , Metabolismo Energético , Hidroxibutiratos/farmacología , 3-Hidroxiacil-CoA Deshidrogenasas , Acetatos/metabolismo , Acetil-CoA C-Aciltransferasa/metabolismo , Acidosis/metabolismo , Oxidorreductasas de Alcohol/metabolismo , Animales , Encéfalo/metabolismo , Dióxido de Carbono/química , Dióxido de Carbono/metabolismo , Corteza Cerebral/metabolismo , Citratos/metabolismo , Creatina Quinasa/metabolismo , Relación Dosis-Respuesta a Droga , Transporte de Electrón , Glucosa/metabolismo , Glutatión/metabolismo , Glicina/análogos & derivados , Glicina/metabolismo , Técnicas In Vitro , Discapacidad Intelectual , Ácido Láctico/metabolismo , NG-Nitroarginina Metil Éster/metabolismo , NG-Nitroarginina Metil Éster/farmacología , Oxígeno/metabolismo , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
Type-1 diabetic patients experience hyperketonemia caused by an increase in fatty acid metabolism. Thus, the aim of this study was to measure the effect of ketone bodies as suppressors of oxidizing species produced by stimulated neutrophils. Both acetoacetate and 3-hydroxybutyrate have suppressive effect on the respiratory burst measured by luminol-enhanced chemiluminescence. Through measurements of hypochlorous acid production, using neutrophils or the myeloperoxidase/H2O2/Cl- system, it was found that acetoacetate but not 3-hydroxybutyrate is able to inhibit the generation of this antimicrobial oxidant. The superoxide anion scavenging properties were confirmed by ferricytochrome C reduction and lucigenin-enhanced chemiluminescence assays. However, ketone bodies did not alter the rate of oxygen uptake by stimulated neutrophils, measured with an oxygen electrode. A strong inhibition of the expression of the cytokine IL-8 by cultured neutrophils was also observed; this is discussed with reference to the antioxidant-like property of acetoacetate.
Asunto(s)
Acetoacetatos/farmacología , Ácido Hipocloroso/antagonistas & inhibidores , Neutrófilos/fisiología , Humanos , Técnicas In Vitro , Interleucina-8/biosíntesis , Cuerpos Cetónicos , Luminiscencia , Neutrófilos/metabolismoRESUMEN
Glucose is the main substrate that fulfills energy brain demands. However, in some circumstances, such as diabetes, starvation, during the suckling period and the ketogenic diet, brain uses the ketone bodies, acetoacetate and beta-hydroxybutyrate, as energy sources. Ketone body utilization in brain depends directly on its blood concentration, which is normally very low, but increases substantially during the conditions mentioned above. Glutamate neurotoxicity has been implicated in neurodegeneration associated with brain ischemia, hypoglycemia and cerebral trauma, conditions related to energy failure, and to elevation of glutamate extracellular levels in brain. In recent years substantial evidence favoring a close relation between glutamate neurotoxic potentiality and cellular energy levels, has been compiled. We have previously demonstrated that accumulation of extracellular glutamate after inhibition of its transporters, induces neuronal death in vivo during energy impairment induced by glycolysis inhibition. In the present study we have assessed the protective potentiality of the ketone body, acetoacetate, against glutamate-mediated neuronal damage in the hippocampus of rats chronically treated with the glycolysis inhibitor, iodoacetate, and in hippocampal cultured neurons exposed to a toxic concentration of iodoacetate. Results show that acetoacetate efficiently protects against glutamate neurotoxicity both in vivo and in vitro probably by a mechanism involving its role as an energy substrate.
Asunto(s)
Acetoacetatos/farmacología , Glucólisis/efectos de los fármacos , Hipocampo/citología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Acetoacetatos/sangre , Adenosina Trifosfato/análisis , Adenosina Trifosfato/metabolismo , Animales , Supervivencia Celular , Células Cultivadas , Ácidos Dicarboxílicos/efectos adversos , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Vías de Administración de Medicamentos , Esquema de Medicación , Interacciones Farmacológicas , Embrión de Mamíferos , Inhibidores Enzimáticos/efectos adversos , Antagonistas de Aminoácidos Excitadores/farmacología , Femenino , Ácido Glutámico/farmacología , Hipocampo/efectos de los fármacos , Yodoacetatos/efectos adversos , Masculino , Fármacos Neuroprotectores/sangre , Inhibidores de la Captación de Neurotransmisores/efectos adversos , Embarazo , Pirrolidinas/efectos adversos , Ácido Pirúvico/farmacología , Quinoxalinas/farmacología , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
Impairment of glutamate uptake or the reverse action of its transporters has been suggested as the mechanism responsible for the increased glutamate extracellular levels associated with ischemic neuronal damage. In previous studies we have shown that glutamate uptake inhibition by L-trans-pyrrolidine-2,4-dicarboxylate (PDC) in the rat striatum and hippocampus in vivo does not induce neuronal death despite the notable increase in the extracellular levels of glutamate and aspartate. However, PDC intracerebral administration leads to neuronal death in rats chronically injected with the mitochondrial toxin 3-nitropropionic acid (3-NP), an inhibitor of succinate dehydrogenase (SDH). In the present study we have determined the time course of inhibition of SDH activity in the striatum of rats acutely injected with a single dose of 3-NP (20 mg/kg), and studied its relation to PDC neurotoxicity. PDC induced larger lesions when administered during maximum inhibition of SDH activity while smaller lesions were found when it was injected during recovery of enzyme activity. We also studied the neuroprotective effect of different energy substrates such as creatine, pyruvate, and the ketone bodies beta-hydroxybutyrate and acetoacetate in this experimental model. Our results show partial protection with all compounds except for beta-hydroxybutyrate that showed no protection, while MK-801 completely prevented PDC-induced neuronal damage. We believe that the present results might be of relevance for the understanding of the mechanisms responsible for ischemic neuronal death and its prevention.
Asunto(s)
Sistema de Transporte de Aminoácidos X-AG/metabolismo , Isquemia Encefálica/enzimología , Metabolismo Energético/fisiología , Degeneración Nerviosa/enzimología , Fármacos Neuroprotectores/farmacología , Neurotoxinas/farmacología , Succinato Deshidrogenasa/metabolismo , Ácido 3-Hidroxibutírico/farmacología , Acetoacetatos/farmacología , Sistema de Transporte de Aminoácidos X-AG/antagonistas & inhibidores , Animales , Isquemia Encefálica/fisiopatología , Convulsivantes/farmacología , Creatina/farmacología , Ácidos Dicarboxílicos/farmacología , Interacciones Farmacológicas/fisiología , Metabolismo Energético/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Ácido Glutámico/metabolismo , Masculino , Neostriado/efectos de los fármacos , Neostriado/enzimología , Neostriado/fisiopatología , Degeneración Nerviosa/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/enzimología , Inhibidores de la Captación de Neurotransmisores/farmacología , Nitrocompuestos , Propionatos/farmacología , Pirrolidinas/farmacología , Ácido Pirúvico/farmacología , Ratas , Ratas Wistar , Succinato Deshidrogenasa/antagonistas & inhibidoresRESUMEN
Acetoacetate, an NADH oxidant, stimulated the ruthenium red-insensitive rat liver mitochondrial Ca(2+) efflux without significant release of state-4 respiration, disruption of membrane potential (Deltapsi) or mitochondrial swelling. This process is compatible with the opening of the currently designated low conductance state of the permeability transition pore (PTP) and, under our experimental conditions, was associated with a partial oxidation of the mitochondrial pyridine nucleotides. In contrast, diamide, a thiol oxidant, induced a fast mitochondrial Ca(2+) efflux associated with a release of state-4 respiration, a disruption of Deltapsi and a large amplitude mitochondrial swelling. This is compatible with the opening of the high conductance state of the PTP and was associated with extensive oxidation of pyridine nucleotides. Interestingly, the addition of carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone to the acetoacetate experiment promoted a fast shift from the low to the high conductance state of the PTP. Both acetoacetate and diamide-induced mitochondrial permeabilization were inhibited by exogenous catalase. We propose that the shift from a low to a high conductance state of the PTP can be promoted by the oxidation of NADPH. This impairs the antioxidant function of the glutathione reductase/peroxidase system, strongly strengthening the state of mitochondrial oxidative stress.
Asunto(s)
Canales Iónicos , Proteínas de la Membrana/metabolismo , Mitocondrias Hepáticas/metabolismo , NADP/metabolismo , NAD/metabolismo , Estrés Oxidativo , Acetoacetatos/farmacología , Animales , Calcio/metabolismo , Carbonil Cianuro p-Trifluorometoxifenil Hidrazona/farmacología , Respiración de la Célula/efectos de los fármacos , Diamida/farmacología , Conductividad Eléctrica , Femenino , Membranas Intracelulares/efectos de los fármacos , Membranas Intracelulares/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Mitocondrias Hepáticas/efectos de los fármacos , Proteínas de Transporte de Membrana Mitocondrial , Poro de Transición de la Permeabilidad Mitocondrial , Dilatación Mitocondrial/efectos de los fármacos , Oxidantes/farmacología , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Permeabilidad/efectos de los fármacos , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Especificidad por Sustrato , Reactivos de Sulfhidrilo/farmacología , Desacopladores/farmacologíaRESUMEN
Experiments in this paper demonstrate that mitochondrial damage associated to NAD(P)+-induced Ca2+ efflux, is the consequence of inappropriate reaction conditions. The major findings are (i) Added oxaloacetate and acetoacetate readily oxidize NAD(P)H in intact rat liver mitochondria without causing swelling or membrane damage. (ii) Ca2+ efflux can be induced by the oxidized state of mitochondrial NADP in the presence of ATP, ADP, Pi and Mg2+, without mitochondrial swelling. (iii) Ca2+ efflux induced by NADP+ in the presence of ruthenium red causes no significant impairment of respiratory control, a sensitive measure of membrane potential.
Asunto(s)
Calcio/metabolismo , Mitocondrias Hepáticas/metabolismo , NADP/farmacología , Consumo de Oxígeno/efectos de los fármacos , Acetoacetatos/farmacología , Animales , Medios de Cultivo , Cinética , Masculino , Mitocondrias Hepáticas/efectos de los fármacos , Dilatación Mitocondrial/efectos de los fármacos , Oxaloacetatos/farmacología , Ratas , Ratas EndogámicasRESUMEN
Lactate, pyruvate, acetone, acetoacetate, and beta-hydroxybutyrate were tested for their bilirubin-displacing effect on human serum albumin. Only lactate had a significant effect at levels found in asphyxiated infants (up to 20 mM). The reserve albumin equivalent for binding bilirubin was determined, using the deputy ligand monoacetyldiaminodiphenyl sulfone (MADDS), in adult human serum albumin solution, neonatal serum, and neonatal albumin solution. Twenty mM lactate caused a 23% decrease of reserve albumin when adult albumin was used, but did not cause any change of binding when neonatal serum or neonatal albumin solution was used. It is unlikely that endogenous substances, acting as competitive ligands, cause the low binding affinity of albumin for bilirubin in sick, premature infants.